Definium Therapeutics is trading 5.06% down now at $42.64 amid a mixed-to-lower market, with the Nasdaq Composite down 0.57% and risk assets pressured by elevated Treasury yields and geopolitical concerns.
- No new company-specific announcement or filing dated August 24, 2026, was identified.
- Latest major company news was positive Phase 3 Voyage data released August 12.
- Today’s decline appears primarily market- and flow-driven rather than catalyst-specific.